Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

LUNG CANCER

Tiragolumab active in PD-L1+ NSCLC

Nature Reviews Clinical Oncology volume 19, page 428 (2022)Cite this article

Subjects

Anti-PD-1/PD-L1 antibodies have dramatically improved the outcomes of many patients with non-small-cell lung cancers (NSCLCs) lacking actionable driver alterations. Nonetheless, the majority of patients do not derive long-term benefit from these agents. Now, data from the phase II CITYSCAPE trial demonstrate the superiority of the anti-TIGIT antibody tiragolumab plus the anti-PD-L1 antibody atezolizumab relative to atezolizumab alone in patients with advanced-stage NSCLC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Chul Cho, B. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol https://doi.org/10.1016/S1470-2045(22)00226-1 (2022)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Peter Sidaway

Authors
  1. Peter Sidaway
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. Tiragolumab active in PD-L1+ NSCLC. Nat Rev Clin Oncol 19, 428 (2022). https://doi.org/10.1038/s41571-022-00650-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-022-00650-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing